Document:

EX-10.6

 Exhibit 10.6 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 MASSACHUSETTS INSTITUTE OF TECHNOLOGY 
 and 

INNOGENE PHARMACEUTICALS, INC. 
 PATENT LICENSE AGREEMENT 
 (EXCLUSIVE) 

  
 -1-

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 TABLE OF CONTENTS 

 

							
	 WITNESSETH
	  	 	1	  
			
	 1
	 	 DEFINITIONS
	  	 	2	  
			
	 2
	 	 GRANT
	  	 	4	  
			
	 3
	 	 DILIGENCE
	  	 	5	  
			
	 4
	 	 ROYALTIES
	  	 	6	  
			
	 5
	 	 REPORTS AND RECORDS
	  	 	8	  
			
	 6
	 	 PATENT PROSECUTION
	  	 	10	  
			
	 7
	 	 INFRINGEMENT
	  	 	10	  
			
	 8
	 	 PRODUCT LIABILITY
	  	 	10	  
			
	 9
	 	 EXPORT CONTROLS
	  	 	12	  
			
	 10
	 	 NON-USE OF NAMES
	  	 	12	  
			
	 11
	 	 ASSIGNMENT
	  	 	12	  
			
	 12
	 	 DISPUTE RESOLUTION
	  	 	13	  
			
	 13
	 	 TERMINATION
	  	 	14	  
			
	 14
	 	 PAYMENTS, NOTICES AND OTHER COMMUNICATIONS
	  	 	15	  
			
	 15
	 	 MISCELLANEOUS PROVISIONS
	  	 	15	  
		
	 APPENDIX A
	  	 	17	  
		
	 APPENDIX B
	  	 	18	  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 MASSACHUSETTS INSTITUTE OF TECHNOLOGY 
 and 
 INNOGENE PHARMACEUTICALS, INC. 

PATENT LICENSE AGREEMENT 
 This Agreement is made and entered into this 11th day of December, 1996 (the “EFFECTIVE DATE”) by and between the MASSACHUSETTS INSTITUTE OF TECHNOLOGY, a corporation duly organized and existing
under the laws of the Commonwealth of Massachusetts and having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, U.S.A. (hereinafter referred to as “M.I.T.”), and Innogene Pharmaceuticals, Inc. a corporation
duly organized under the laws of Delaware and having its principal office at 41 Fresh Pond Lane, Cambridge, MA 02138 (hereinafter referred to as “LICENSEE”). 
 WITNESSETH 
 WHEREAS, M.I.T. is the owner of certain PATENT RIGHTS (as
later defined herein) relating to [***]. 
 WHEREAS M.I.T. is the co-owner with Albert Einstein College of Medicine
(“AECOM”) of the PATENT RIGHTS of [***]; 
 WHEREAS, M.I.T. and AECOM desire to have the PATENT RIGHTS developed and
commercialized to benefit the public and is willing to grant a license thereunder, 
 WHEREAS, LICENSEE has represented to
M.I.T., to induce M.I.T. to enter into this Agreement, that LICENSEE is experienced in the development, production, manufacture, marketing and sale of products similar to the LICENSED PRODUCT(s) (as later defined herein) and/or the use of the
LICENSED PROCESS(es) (as later defined herein) and that it shall commit itself to a thorough, vigorous and diligent program of exploiting the PATENT RIGHTS so that public utilization shall result therefrom; and 

WHEREAS, LICENSEE desires to obtain a license under the PATENT RIGHTS upon the terms and conditions hereinafter set forth. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 NOW, THEREFORE, in consideration of the premises and the mutual covenants contained
herein, the parties hereto agree as follows: 
 1 - DEFINITIONS 

For the purposes of this Agreement, the following words and phrases shall have the following meanings: 

1.1 “LICENSEE” shall include a related company of Innogene Pharmaceuticals, Inc. the voting stock of which is directly or
indirectly at least Fifty Percent (50%) owned or controlled by Innogene Pharmaceuticals, Inc. an organization which directly or indirectly controls more than Fifty Percent (50%) of the voting stock of Innogene Pharmaceuticals, Inc. and an
organization, the majority ownership of which is directly or indirectly common to the ownership of Innogene Pharmaceuticals, Inc. 
 1.2 “PATENT RIGHTS” shall mean all of the following M.I.T. intellectual property: 
  

	 	a.	the United States patents listed in Appendix A; 

  

	 	b.	the United States patent applications listed in Appendix A, and divisionals, continuations and claims of continuation-in-part applications which shall be directed to
subject matter specifically described in such patent applications, and the resulting patents; 

  

	 	c.	any patents resulting from reissues or reexaminations of the United States patents described in a. and b. above; 

 

	 	d.	the Foreign patents listed in Appendix A; 

  

	 	e.	the Foreign patent applications listed in Appendix A, and divisionals, continuations and claims of continuation-in-part applications which shall be directed to subject
matter specifically described in such Foreign patent applications, and the resulting patents; 

  

	 	f.	Foreign patent applications filed after the EFFECTIVE DATE and divisionals, continuations and claims of continuation-in-part applications which shall be directed to
subject matter specifically described in such patent applications, and the resulting patents; and 

  

	 	g.	any Foreign patents, resulting from equivalent Foreign procedures to United States reissues and reexaminations, of the Foreign patents described in d., e. and f. above.

  

	 	h.	any U.S. and foreign patent applications and the resulting patents and any reissues and reexaminations which may be filed on the technology of any of the M.I.T. Cases
in Appendix A, as the technology existed on the Effective Date. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 1.3 A “LICENSED PRODUCT” shall mean any product or part thereof which:

  

	 	a.	is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the PATENT RIGHTS in the country in which any such product or part thereof
is made, used or sold; or 

  

	 	b.	is manufactured by using a process or is employed to practice a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained
in the PATENT RIGHTS in the country in which any LICENSED PROCESS is used or in which such product or part thereof is used or sold. 

 If a claim has been abandoned or judged invalid or unenforceable by a court of competent jurisdiction, or an administrative agency, from which no appeal can be or is taken in any country, then any product
or process falling only under that claim shall not be considered to be a LICENSED PRODUCT or LICENSED PROCESS in that country for the purposes of this Agreement. 
 1.4 A “LICENSED PROCESS” shall mean any process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the PATENT RIGHTS. 

1.5 “NET SALES” shall mean LICENSEE’S billings for LICENSED PRODUCTS and LICENSED- PROCESSES less the sum of the
following: 
  

	 	a.	discounts allowed in amounts customary in the trade for quantity purchases, cash payments, prompt payments, wholesalers and distributors; 

 

	 	b.	sales, tariff duties and/or use taxes directly imposed and with reference to particular sales; 

 

	 	c.	outbound transportation prepaid or allowed; and 

  

	 	d.	amounts allowed or credited on returns. 

 No deductions shall be made for commissions paid to individuals whether they be with independent sales agencies or regularly employed by LICENSEE and on its payroll, or for cost of collections. NET SALES
shall occur when a LICENSED PRODUCT or LICENSED 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
PROCESS shall be invoiced. If a LICENSED PRODUCT or LICENSED PROCESS shall be distributed or invoiced for a discounted price substantially lower than customary in the trade or distributed at no
cost to affiliates or otherwise, NET SALES shall be based on the customary amount billed for such LICENSED PRODUCTS or LICENSED PROCESSES. 
 1.6 “TERRITORY” shall mean [***]. 
 1.7 “FIELD OF USE”
shall mean all. 
 1.8 “TANGIBLE PROPERTY” shall mean the biological materials listed in Appendix B and any
derivatives or progeny thereof. 
 2 - GRANT 
 2.1 M.I.T. hereby grants to LICENSEE the right and license in the TERRITORY for the FIELD OF USE to practice under the PATENT RIGHTS and, to the extent not prohibited by other patents, to make, have made,
use, lease, sell and import LICENSED PRODUCTS and to practice the LICENSED PROCESSES, until the expiration of the last to expire of the PATENT RIGHTS, unless this Agreement shall be sooner terminated according to the terms hereof. 

2.2 LICENSEE agrees that LICENSED PRODUCTS leased or sold in the United States shall be manufactured substantially in the United States.

 2.3 In order to establish a period of exclusivity for LICENSEE, M.I.T. hereby agrees that it shall not grant any other
license to make, have made, use, lease, sell and import LICENSED PRODUCTS or to utilize LICENSED PROCESSES subject to the royalty-free, nonexclusive license rights of the United States Government per FAR 52.227-11, in the TERRITORY for the FIELD OF
USE. 
 2.4 M.I.T. reserves the right to practice under the PATENT RIGHTS for noncommercial research purposes. AECOM reserves
the right to practice under the PATENT RIGHTS of M.I.T. Case No. 7410 for noncommercial research purposes. 
 2.5 M.I.T.
hereby grants to LICENSEE, during the term of this Agreement, an exclusive, royalty-free commercial license to use, reproduce, modify, make derivatives of, and transfer the TANGIBLE PROPERTY in conjunction with the LICENSED PRODUCTS and LICENSED
PROCESSES or as otherwise necessary or useful for the exercise of the PATENT RIGHTS licensed hereunder. LICENSEE shall have the right to sublicense the TANGIBLE 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
PROPERTY within LICENSEE’S reasonable discretion in order to exercise the PATENT RIGHTS granted under this Agreement. M.I.T. reserves the right to use, reproduce, modify, and make
derivatives of the TANGIBLE PROPERTY for non-commercial research purposes. M.I.T. shall make reasonable efforts to transfer to LICENSEE functional samples of the TANGIBLE PROPERTY in their original form as listed in Appendix B, but shall have no
obligation to replace such samples, and makes no warranty of their fitness for use. 
 2.6 M.I.T. reserves the right to
distribute the TANGIBLE PROPERTY for research purposes only, to third parties including commercial entities. 
 2.7 M.I.T. also
grants to LICENSEE a nonexclusive, non-royalty-bearing license to non-tangible know-how associated with the technology of any of the Cases of Appendix A, and further agrees that this know-how may be transferred by LICENSEE to third parties.

 2.8 LICENSEE shall have the right to enter into sublicensing agreements for the rights, privileges and licenses granted
hereunder. Upon any termination of this Agreement, sublicensees’ rights shall be subject to Paragraph 13.6 hereof. 
 2.9
LICENSEE agrees to incorporate terms and conditions substantively similar to Articles 2, 5.1, 7.1, 7.2, 7.3, 7.5, 7.6, 8, 9, 10, 12 and 15 of this Agreement into its sublicense agreements, that are sufficient to enable LICENSEE to comply with this
Agreement. 
 2.10 LICENSEE agrees to forward to M.I.T. a copy of any and all sublicense agreements promptly upon execution by
the parties. 
 2.11 LICENSEE shall not receive from sublicensees anything of value in lieu of cash payments in consideration
for any sublicense under this Agreement, without the express prior written permission of M.I.T. 
 2.12 Nothing in this
Agreement shall be construed to confer any rights upon LICENSEE by implication, estoppel or otherwise as to any technology or PATENT RIGHTS of M.I.T., or any other entity other than the PATENT RIGHTS and TANGIBLE PROPERTY. 

3 - DILIGENCE 
 3.1 LICENSEE shall use diligent efforts to bring LICENSED PRODUCTS to market through a thorough, vigorous program for exploitation of the PATENT RIGHTS and to continue active, diligent development and
marketing efforts for LICENSED PRODUCTS throughout the life of this Agreement. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 3.2 LICENSEE shall raise a cumulative total of investment capital of at least:

  

	 	a.	[***]; and 

  

	 	b.	[***]; and 

  

	 	c.	[***]. 

 3.3 [***] 

 

	 	a.	[***]; 

  

	 	b.	[***]; 

  

	 	c.	[***]; and 

  

	 	d.	[***]. 

 3.4 LICENSEE’S
failure to perform in accordance with either Paragraph 3.1 or 3.2 above shall be grounds for M.I.T. to terminate this Agreement pursuant to Paragraph 13.3 hereof, provided, however, if LICENSEE has expended at least [***], and is otherwise in
compliance with the terms and conditions of this Agreement, the license under this Agreement will become nonexclusive, without the right to sublicense, except by approval of M.I.T., such approval not to be unreasonably withheld. 

4 - ROYALTIES 
 4.1 For the rights, privileges and license granted hereunder, LICENSEE shall pay royalties to M.I.T. in the manner hereinafter provided to the end of the term of the PATENT RIGHTS or until this Agreement
shall be terminated: 
  

	 	a.	License Issue Fee of [***], which said License Issue Fee shall be deemed earned and due in three parts: 

 

	 	(i)	[***] due upon the signing of the Agreement; and 

  

	 	(ii)	[***] due upon the raising of Two Million Dollars ($2,000,000) in investment capital by LICENSEE. 

 

	 	(iii)	[***] upon the filing by LICENSEE of a New Drug Application for the first LICENSED PRODUCT. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

	 	b.	License Maintenance Fees of [***] per year payable on January 1, 1999 and on January 1 of each year thereafter, provided, however, License Maintenance Fees
may be credited to Running Royalties subsequently due on NET SALES for each said year, if any. License Maintenance Fees paid in excess of Running Royalties shall not be creditable to Running Royalties for future years. 

 

	 	c.	Running Royalties in an amount equal to [***] of NET SALES of the LICENSED PRODUCTS and LICENSED PROCESSES used, leased or sold by and/or for LICENSEE.

  

	 	d.	The following proportion of payments, including, but not limited to, sublicense issue fees and royalties, received from sublicensees in consideration for the LICENSED
PRODUCTS and LICENSED PROCESSES, but excluding payments made for research funding: 

  

	 	(i)	[***]; or 

  

	 	(ii)	[***]. 

 Provided, however, that
in no case shall the payments for each sublicense in any given year be less than [***] of the net sales of the sublicensee in that year, determined on the same basis on which such net sales are reported to LICENSEE for purposes of determining
royalties payable to LICENSEE under its sublicense. 
 Net sales shall be determined on substantially the same terms as
“NET SALES” are defined herein, with only such changes as M.I.T. may approve, which approval shall not be unreasonably withheld. 
 4.2 If LICENSEE must pay royalties to a third party for patents necessary to the reduction or sale LICENSED PRODUCTS or LICENSED PROCESSES, LICENSEE may credit [***] of the royalties paid to the third
party against the Running Royalties otherwise due under P. 4.1 (c) above, provided that in no event shall the amount paid to M.I.T. for that LICENSED PRODUCT or LICENSED PROCESS be less than [***] of the NET SALES of that LICENSED PRODUCT or
LICENSED PROCESS. 
 4.3 No royalties shall be due on any LICENSED PRODUCT or LICENSED PROCESS which falls only under a pending
patent which has not issued five years following its 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
priority date. If a patent subsequently issues, royalties on the LICENSED PRODUCT or LICENSED PROCESS shall resume from the issue date of such patent. If a patent subsequently issues, royalties
on the LICENSED PRODUCT or LICENSED PROCESS shall resume from the issue date of such patent. 
 4.4 If LICENSEE sells a LICENSED
PRODUCT or LICENSED PROCESS which delivers several active genes (totaling “B”), the delivery of only “A” of which fall under the PATENT RIGHTS, then the NET SALES for the purposes of the Running Royalties of P.4.1(c) and 4.1(d)
above shall be [***]. 
 4.5 All payments due hereunder shall be paid in full, without deduction of taxes or other fees which
may be imposed by any government, except as otherwise provided in Paragraph 1.5(b). 
 4.6 If LICENSEE is prevented from [***],
then LICENSEE shall not be required to pay to M.I.T. [***]. 
 4.7 No multiple royalties shall be payable because any LICENSED
PRODUCT, its manufacture, use, lease or sale are or shall be covered by more than one PATENT RIGHTS patent application or PATENT RIGHTS patent licensed under this Agreement. 
 4.8 Royalty payments shall be paid in United States dollars in Cambridge, Massachusetts, or at such other place as M.I.T. may reasonably designate consistent with the laws and regulations controlling in
any foreign country. If any currency conversion shall be required in connection with the payment of royalties hereunder, such conversion shall be made by using the exchange rate prevailing at the Chase Manhattan Bank (N.A.) on the last business day
of the calendar quarterly reporting period to which such royalty payments relate. 
 5 - REPORTS AND RECORDS 

5.1 LICENSEE shall keep full, true and accurate books of account containing all particulars that may be necessary for the purpose of
showing the amounts payable to M.I.T. hereunder. Said books of account shall be kept at LICENSEE’S principal place of business or the principal place of business of the appropriate division of LICENSEE to which this Agreement relates. Said
books and the supporting data shall be open at all reasonable times[***] for five (5) years following the end of the calendar year to which they pertain, to the inspection 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
of a M.I.T. agent, who shall be an accounting firm of national standing, for the purpose of verifying LICENSEE’S royalty statement or compliance in other respects with this Agreement. Should
such inspection lead to the discovery of a greater than [***] discrepancy in reporting to M.I.T.’s detriment, LICENSEE agrees to pay the full cost of such inspection. 
 5.2 LICENSEE shall deliver to M.I.T. true and accurate reports, giving such particulars of the business conducted by LICENSEE and its sublicensees under this Agreement as shall be pertinent to diligence
under Article 3 and royalty accounting hereunder: 
  

	 	a.	before the first commercial sale of a LICENSED PRODUCT or LICENSED PROCESS, annually, on January 31 of each year; and 

 

	 	b.	after the first commercial sale of a LICENSED PRODUCT or LICENSED PROCESS, quarterly, within sixty (60) days after
March 31, June 30, September 30 and December 31, of each year. 

 These reports
shall include at least the following: 
  

	 	a.	[***]; 

  

	 	b.	[***]; 

  

	 	c.	[***]; 

  

	 	d.	[***]; 

  

	 	e.	[***]; 

  

	 	f.	[***]; and 

  

	 	g.	[***]. 

 5.3 With each such
report submitted, LICENSEE shall pay to M.I.T. the royalties due and payable under this Agreement. If no royalties shall be due, LICENSEE shall so report. 
 5.4 On or before the ninetieth (90th) day following the close of LICENSEE’S fiscal year, LICENSEE shall provide M.I.T. with LICENSEE’S certified financial statements for the preceding
fiscal year including, at a minimum, a balance sheet and an income statement. 
 5.5 The amounts due under Articles 4 and 6
shall, if overdue, bear interest until payment at a per annum rate [***]. The payment of such interest shall not foreclose M.I.T. from exercising any other rights it may have as a consequence of the lateness of any payment. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 6 - PATENT PROSECUTION 

6.1 Upon the Effective Date, LICENSEE shall assume responsibility for the filing, prosecution and maintenance of the PATENT RIGHTS in the
U.S. and in foreign countries elected by LICENSEE, using a patent attorney of LICENSEE’S choice. Such prosecution shall be in M.I.T.’s name. LICENSEE shall not abandon any substantive claim or fail to make a payment with respect to any of
the PATENT RIGHTS filed by M.I.T. prior to the Effective Date in the U.S., Canada, the countries of the European Patent Office, or Japan unless LICENSEE has notified M.I.T. in sufficient time for M.I.T. to assume such prosecution or make payment at
its own expense. M.I.T. shall be copied on all correspondence with government patent offices relating to prosecution and maintenance of the PATENT RIGHTS, M.I.T. shall have reasonable opportunities to advise LICENSEE and shall cooperate with
LICENSEE in such filing, prosecution and maintenance. 
 6.2 Payment of all fees and costs relating to the filing, prosecution
and maintenance of the PATENT RIGHTS shall be the responsibility of [***]. 
 7 - INFRINGEMENT 

7.1 LICENSEE and M.I.T. shall each inform the other promptly in writing of any alleged infringement of the PATENT RIGHTS by any third
party that comes to the notifying party’s attention and of any available evidence thereof of which the notifying party is aware. 
 7.2 [***] 
 7.3 [***] 

7.4 [***] 
 7.5
[***] 
 7.6 [***] 
 7.7 [***] 
 8 - PRODUCT LIABILITY 

8.1 LICENSEE shall at all times during the term of this Agreement and thereafter, indemnify, defend and hold M.I.T, AECOM, their
trustees, directors, officers, employees and affiliates, harmless against all claims, proceedings, demands and liabilities of any kind 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
whatsoever, including legal expenses and reasonable attorneys’ fees, arising out of the death of or injury to any person or persons or out of any damage to property, resulting from the
production, manufacture, sale, use, lease, consumption or advertisement of the LICENSED PRODUCT(s) and/or LICENSED PROCESS(es) and/or TANGIBLE PROPERTY or arising from any obligation of LICENSEE hereunder. 

8.2 LICENSEE shall obtain and carry in full force and effect commercial, general liability insurance, including product liability and
errors and omissions insurance, which shall protect LICENSEE, M.I.T. and AECOM with respect to events covered by Paragraph 8.1 above. Such insurance shall be written by a reputable insurance company authorized to do business in the Commonwealth of
Massachusetts, shall list M.I.T. as an additional named insured thereunder, shall be endorsed to include product liability coverage and shall require thirty (30) days written notice to be given to M.I.T. prior to any cancellation or material
change thereof. The limits of such insurance shall not be less than [***]. LICENSEE shall provide M.I.T. with Certificates of Insurance evidencing the same. 
 8.3 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, M.I.T., ALBERT EINSTEIN COLLEGE OF MEDICINE (AECOM), THEIR TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AND AFFILIATES MAKE NO REPRESENTATIONS
AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER
DEFECTS, WHETHER OR NOT DISCOVERABLE. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY M.I.T. OR AECOM THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF
ANY THIRD PARTY. IN NO EVENT SHALL M.I.T. OR AECOM, THEIR TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS,
REGARDLESS OF WHETHER M.I.T. OR AECOM SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 9 - EXPORT CONTROLS 

LICENSEE acknowledges that it is subject to United States laws and regulations controlling the export of technical data, computer
software, laboratory prototypes and other commodities (including the Arms Export Control Act, as amended and the United States Department of Commerce Export Administration Regulations). The transfer of such items may require a license from the
cognizant agency of the United States Government and/or written assurances by LICENSEE that LICENSEE shall not export data or commodities to certain foreign countries without prior approval of such agency. M.I.T. neither represents that a license
shall not be required nor that, if required, it shall be issued. 
 10 - NON-USE OF NAMES 

LICENSEE shall not use the names or trademarks of the Massachusetts Institute of Technology or Lincoln Laboratory, nor Albert Einstein
College of Medicine (AECOM), nor any adaptation thereof, nor the names of any of their employees, in any advertising, promotional or sales literature without prior written consent obtained from M.I.T., AECOM, or said employee, in each case, except
that LICENSEE may state that it is licensed by M.I.T. under one or more of the patents and/or applications comprising the PATENT RIGHTS. 
 11 - ASSIGNMENT 
 This Agreement is not assignable except to successors of
substantially all of LICENSEE’S business related to the subject matter of this Agreement, by merger or other operation of law, and in the case a merger in which the stockholders of LICENSEE will own less than 50% of the outstanding voting power
of the resulting corporation, with the consent of M.I.T., such consent not to be unreasonably withheld. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 12 - DISPUTE RESOLUTION 

12.1 Except for the right of either party to apply to a court of competent jurisdiction for a temporary restraining order, a preliminary
injunction, or other equitable relief to preserve the status quo or prevent irreparable harm, any and all claims, disputes or controversies arising under, out of, or in connection with the Agreement, including any dispute relating to patent validity
or infringement, which the parties shall be unable to resolve within [***] shall be mediated in good faith. The party raising such dispute shall promptly advise the other party of such claim, dispute or controversy in a writing which describes in
reasonable detail the nature of such dispute. By not later than [***] after the recipient has received such notice of dispute, each party shall have selected for itself a representative who shall have the authority to bind such party, and shall
additionally have advised the other party in writing of the name and title of such representative. By not later than [***] after the date of such notice of dispute, the party against whom the dispute shall be raised shall select a mediation firm in
the Boston area and such representatives shall schedule a date with such firm for a mediation hearing. The parties shall enter into good faith mediation and shall share the costs equally. If the representatives of the parties have not been able to
resolve the dispute within [***] after such mediation hearing, then any and all claims, disputes or controversies arising under, out of, or in connection with this Agreement, including any dispute relating to patent validity or infringement, shall
be resolved by final and binding arbitration in Boston, Massachusetts under the rules of the American Arbitration Association, or the Patent Arbitration Rules if applicable, then obtaining. The arbitrators shall have no power to add to, subtract
from or modify any of the terms or conditions of this Agreement, nor to award punitive damages. Any award rendered in such arbitration may be enforced by either party in either the courts of the Commonwealth of Massachusetts or in the United States
District Court for the District of Massachusetts, to whose jurisdiction for such purposes M.I.T. and LICENSEE each hereby irrevocably consents and submits. 
 12.2 Notwithstanding the foregoing, nothing in this Article shall be construed to waive any rights or timely performance of any obligations existing under this Agreement. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 13 - TERMINATION 

13.1 If LICENSEE shall cease to carry on its business, this Agreement shall terminate upon notice by M.I.T. 

13.2 Should LICENSEE fail to make any payment whatsoever due and payable to M.I.T. hereunder, M.I.T. shall have the right to terminate
this Agreement effective on thirty (30) days’ notice, unless LICENSEE shall make all such payments to M.I.T. within said thirty (30) day period. Upon the expiration of the thirty (30) day period, if LICENSEE shall not have made
all such payments to M.I.T., the rights, privileges and license granted hereunder shall automatically terminate. 
 13.3 Upon
any material breach or default of this Agreement by LICENSEE (including, but not limited to, breach or default under Paragraph 3.3), other than those occurrences set out in Paragraphs 13.1 and 13.2 hereinabove, which shall always take precedence in
that order over any material breach or default referred to in this Paragraph 13.3, M.I.T. shall have the right to terminate this Agreement and the rights, privileges and license granted hereunder effective on ninety (90) days’ notice to
LICENSEE. Such termination shall become automatically effective unless LICENSEE shall have cured any such material breach or default prior to the expiration of the ninety (90) day period. 

13.4 LICENSEE shall have the right to terminate this Agreement at any time on six (6) months’ notice to M.I.T., and upon
payment of all amounts due M.I.T. through the effective date of the termination. 
 13.5 Upon termination of this Agreement for
any reason, nothing herein shall be construed to release either party from any obligation that matured prior to the effective date of such termination; and Articles 1, 8, 9, 10, 12, 13.5, 13.6, and 15 shall survive any such termination. LICENSEE and
any sublicensee thereof may, however, after the effective date of such termination sell all LICENSED PRODUCTS, and complete LICENSED PRODUCTS in the process of manufacture at the time of such termination and sell the same, provided that LICENSEE
shall make the payments to M.I.T. as required by Article 4 of this Agreement and shall submit the reports required by Article 5 hereof. 
 13.6 Upon termination of this Agreement for any reason, any sublicensee not then in default shall remain in force and effect in accordance with its terms, with M.I.T. taking the place of LICENSEE, but not
subject to any performance obligations of LICENSEE. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 14 - PAYMENTS, NOTICES AND OTHER COMMUNICATIONS 

Any payments, notice or other communication pursuant to this Agreement shall be sufficiently made or given on the date of mailing if sent
to such parry by certified first class mail, return receipt requested, postage prepaid, addressed to it at its address below or as it shall designate by written notice given to the other party: 

In the case of M.I.T.: 
 Director 
 Technology Licensing Office 

Massachusetts Institute of Technology 
 77 Massachusetts Avenue, NE25-230 
 Cambridge, Massachusetts 02139 

In the case of LICENSEE: 
 Innogene Pharmaceuticals, Inc. 
 41 Fresh Pond Lane 

Cambridge, MA 02138 
 15 - MISCELLANEOUS PROVISIONS 
 15.1 All disputes arising out of or related
to this Agreement, or the performance, enforcement, breach or termination hereof, and any remedies relating thereto, shall be construed, governed, interpreted and applied in accordance with the laws of the Commonwealth of Massachusetts, U.S.A.,
except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted. 
 15.2 The parties hereto acknowledge that this Agreement sets forth the entire Agreement and understanding of the parties hereto as to the subject matter hereof, and shall not be subject to any change or
modification except by the execution of a written instrument signed by the parties. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 15.3 The provisions of this Agreement are severable, and in the event that any
provisions of this Agreement shall be determined to be invalid or unenforceable under any controlling body of the law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof.

 15.4 LICENSEE agrees to mark the LICENSED PRODUCTS sold in the United States with all applicable United States patent
numbers. All LICENSED PRODUCTS shipped to or sold in other countries shall be marked in such a manner as to conform with the patent laws and practice of the country of manufacture or sale. 

15.5 The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement
shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. 
 IN WITNESS WHEREOF, the parties have duly executed this Agreement the day and year set forth below. 
  

									
	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	 		 	INNOGENE PHARMACEUTICALS, INC.
					
	By	 	 /s/ Lita Nelsen
	 		 	By	 	 /s/ Irving M. London

					
	Name	 	 Lita L. Nelsen, Director
	 		 	Name	 	 Irving M. London

					
	Title	 	 Technology Licensing Office
	 		 	Title	 	 President

					
	Date	 	 Dec 18, 1996
	 		 	Date	 	 Dec 18, 1996

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 APPENDIX A 
 PATENT RIGHTS on the EFFECTIVE DATE 
 UNITED STATES PATENT RIGHTS 

[***] 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 APPENDIX B 
 DESIGNATED FOREIGN COUNTRIES 
 Foreign countries in which PATENT RIGHTS shall be filed, prosecuted
and maintained accordance with Article 6: 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 FIRST AMENDMENT 

This First Amendment, effective as of the date set forth above the signatures of the parties below, is between the Massachusetts
Institute of Technology (“M.I.T.”), a Massachusetts corporation having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts, 02139 and Genetix Pharmaceuticals, Inc. (“COMPANY”), a Delaware corporation, with a
principal place of business at 840 Memorial Drive, Cambridge, Massachusetts 02139. 
 WHEREAS, COMPANY and M.I.T. wish to modify
the provisions of the Exclusive Patent License Agreement dated December 18, 1996 as amended, (“LICENSE AGREEMENT”). 
 NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, the parties hereby agree to modify the LICENSE AGREEMENT as follows: 

 

	 	1.	The following text shall be added to the end of Appendix A: 

 [***] 
  

	 	2.	Section 4.1.b shall be changed such that [***] shall be deleted and replaced with [***]. 

 

	 	3.	A Case Addition Fee for MIT Case 10104 [***] shall be due February 1, 2004. 

 The remaining terms and conditions of the LICENSE AGREEMENT remain intact. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed under seal by
their duly authorized representatives. 
 The Effective Date of this First Amendment is December 12, 2003. 

 

									
	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	 		 	GENETIX PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Lita Nelsen
	 		 	By:	 	 /s/ Ronald Dorazio MD

					
	Name:	 	 Lita L. Nelsen, Director
	 		 	Name:	 	 Ronald Dorazio, MD

					
	Title:	 	 Technology Licensing Office
	 		 	Title:	 	 Vice President

					
	Date:	 	 12/22/03
	 		 	Date:	 	 Dec. 17, 2003

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 SECOND AMENDMENT 

WHEREAS the Massachusetts Institute of Technology (“MIT”) and Genetix Pharmaceuticals Inc. of Cambridge, Massachusetts
(“Genetix” or “Company,” formerly Innogene Pharmaceuticals, Inc.) are parties to the Patent License Agreement (“License Agreement”) entered into on December 18, 1996; and 

WHEREAS Genetix currently lacks sufficient cash funds to substantially advance the development of its lead product candidate
LentiGlobinTM which incorporates technology subject to the License Agreement or to make further payments under the License Agreement which could become due; and 
 WHEREAS Genetix has entered into a subsequent letter agreement (“Letter Agreement”) with MIT dated April 9, 2004 and providing for conditional retraction of MIT’s earlier Letter of
Termination upon a financing of Genetix and certain payments by Genetix to MIT, as well as a further agreement (“First Amendment”) dated December 12, 2003 amending the License Agreement to incorporate certain new technology and
payments by Genetix; and 
 WHEREAS Genetix’ lead product in development, LentiGlobinTM, incorporates multiple
technologies requiring licenses from multiple parties each bearing royalty, license fee, and sublicensing terms which are substantial and in the case of sublicensing terms are prohibitive in and of themselves, and Genetix now anticipates requirement
for an additional license from at least one further party; and 
 WHEREAS [***]; and 

WHEREAS Genetix has not entered into any sublicense under the License Agreement nor has it initiated negotiation of such a sublicense;
and 
 WHEREAS Genetix desires to realize the equity investment so that it may continue operations and advance LentiGlobinTM
into human clinical trials, and Genetix has therefore proposed to MIT to amend Section 4.1.d of the License Agreement to eliminate the requirement for certain payments to made pursuant to future sublicenses, for the satisfaction of new
investors; and 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 WHEREAS MIT stands to benefit financially from receipt by Genetix of the investment,
through the intended further development and potential commercialization of LentiGlobinTM under the License Agreement as amended below; 
 Now, therefore, MIT and Genetix agree as follows (the “Second Amendment”): 
 1. The first sentence of Section 4.1.d of the License Agreement shall be amended and replaced with the following: 
 “The following proportion of payments received from sublicensees in consideration for the LICENSED PRODUCTS and LICENSED PROCESSES: 

 

	 	i.	[***]; or 

  

	 	ii.	[***].” 

 The remainder of
the same Section, beginning “Provided, however...” shall remain as previously agreed and written. 
 2. The License
Agreement, the Letter Agreement, the First Amendment, and this Second Amendment reflect the entire Agreement between MIT and Genetix. This Agreement may only be modified in writing signed by a duly authorized representative of MIT and a duly
authorized representative of Genetix. 
  

									
	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	 		 	GENETIX PHARMACEUTICALS, INC.
			
	 /s/ Lita Nelsen
	 		 	 /s/ Walter C. Ogier

			
	Lita Nelsen, Director, Technology Licensing Office	 		 	Walter C. Ogier, President and CEO
					
	Dated:	 	 May 6, 2004
	 		 	Dated:	 	 May 6, 2004

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 THIRD AMENDMENT 
 This Amendment is to the license agreement dated December 11, 1996 between Massachusetts Institute of Technology and Bluebird Bio Inc. (formerly Innogene Pharmaceuticals, Inc., formerly Genetix
Pharmaceuticals Inc.), hereinafter referred to as “LICENSEE”, as subsequently amended by the First Amendment dated December 12, 2003 and the Second Amendment dated May 6, 2004. 

The parties hereby further agree as follows: 
  

	 	1.	The annual License Maintenance Fee payments of Paragraph 4.1(b) shall be changed to [***] per year. 

 

	 	2.	Paragraph 4.1(c) shall be replaced with the following: 

 Running Royalties in an amount equal to [***] of NET SALES of LICENSED PRODUCTS and LICENSED PROCESSES used, leased and/or sold by LICENSEE or its SUBLICENSEES: 

 

	 	3.	Paragraph 4.1 (d), as amended in the Second Amendment, shall be replaced with the following: 

(i) If only the PATENT RIGHTS are sublicensed: [***]; excluding however: 

 

	 	((a))	[***]; and 

  

	 	((b))	[***]; and 

  

	 	((c))	[***]. 

 (ii) If
the sublicense revenue is paid for a package including the PATENT RIGHTS and products developed by LICENSEE and/or substantial technology and/or intellectual property developed by LICENSEE: [***]; excluding, however:

  

	 	((a))	[***]; and 

  

	 	((b))	[***]; and 

  

	 	((c))	[***]; and 

  

	 	((d))	[***]. 

  

	 	4.	Section 4.2 shall be deleted and replaced in its entirety by: 

  

	 	4.2	 If LICENSEE (or its SUBLICENSEE) must pay royalties to a third party for patents necessary to the production or sale of LICENSED PRODUCTS or

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

	 	
LICENSED PROCESSES, LICENSEE may credit [***] of the royalties paid to the third party against the Running Royalties otherwise due under P.4.1 (c) above, provided that in no event
shall the amount paid to M.I.T. for that LICENSED PRODUCT or LICENSED PROCESS be less than [***] of NET SALES. 

 This
Amendment with the effective date of June 1, 2011 is hereby agreed to by: 
  

									
	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	 		 	BLUEBIRD BIO, INC.
					
	By:	 	 /s/ Lita Nelsen
	 		 	By:	 	 /s/ Nick Leschly

					
	Name:	 	 Lita L. Nelsen, Director
	 		 	Name:	 	 Nick Leschly

					
	Title: 	 	 Technology Licensing Office
	 		 	Title:	 	 CEOEX-10.8

 Exhibit 10.8 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 LICENSE AGREEMENT 
 Between 
 INSTITUT PASTEUR, a non profit private foundation organized under the laws of France with offices at 25-28 rue du Docteur Roux, 75 724 Paris Cedex 15, France, VAT FR 65 775 684 897, represented by
M. Christophe Mauriet, Senior Executive Vice-President for Administration, and M. Jean Derégnaucourt, Executive Vice President Business Development 
 Hereinafter referred to as “Institut Pasteur” 
 On one hand, 

And 
 BLUEBIRDBIO INC., a company
incorporated under the laws of Massachusetts, with offices at 840 Memorial Drive, Cambridge, MA 02139, United States, represented by Nick Leschly, Chief Executive Officer 
 Hereinafter referred to as “Licensee”, 
 On the other hand, 

Hereinafter mentioned as a Party or the Parties. 
 Recitals 
 1. Institut Pasteur has identified and patented a specific nucleotide sequence
having a triplex structure, hereinafter referred to as “DNA flap”, covered by patents and patent applications. 
 2. Institut Pasteur
has granted several exclusive or non exclusive licenses on the DNA flap under several fields to companies. 
 3. Licensee is a company
developing innovative gene therapies for severe genetic disorders. 
 4. Licensee wishes to obtain a license of such patents and commercialize
products for gene therapy. 
 5. Licensee and Institut Pasteur have decided to discuss terms of a license agreement according to the terms and
conditions of this Agreement. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 Now, therefore, the Parties hereby agree as follow: 

Article 1. Definitions 
 For the purpose
of this Agreement, the terms used in this Agreement, in singular or in plural, shall have the respective meanings set forth below: 
  

	 	•	 	 “Affiliate” means with respect to Licensee any party which (directly or indirectly) is controlled by, controls, or is under common
control with, Licensee. For the purposes of this definition, the terms “control” and “controlled” mean the direct or indirect ownership of more than fifty percent (50%) of the outstanding voting securities of an entity, or
such other relationship as results in actual control over the management, assets, business and affairs of such entity. 

  

	 	•	 	 “Agreement” shall mean this license agreement together with its appendices which make integral part of it. 

 

	 	•	 	 “Confidential Information” shall mean any and all confidential information, whatever its nature or its format, which is disclosed by one
Party to the other Party hereunder and that is marked confidential or with similar term, if disclosed in writing, or if disclosed orally, identified as confidential at the time of disclosure. Notwithstanding the foregoing, any information which, by
its nature and under the circumstances surrounding its disclosure is generally considered proprietary and confidential shall be deemed Confidential Information regardless of whether it is properly marked with legends or properly reduced to writing.

  

	 	•	 	 “Development Plan” shall mean a document defining the research and development of the Licensee and/or Affiliates as well as the commercial
and financial development estimates of Licensee and/or Affiliates for its Product(s) using the Technology in the Field. 

  

	 	•	 	 “Effective Date” shall mean the date of the last signature of this Agreement by the Parties. 

 

	 	•	 	 “Ex vivo gene therapy” shall mean that cells are extracted from a patient, corrected by placing a healthy or functional gene(s) and
transplanted back into patient. 

  

	 	•	 	 “Field” shall mean ex vivo gene therapy for human disorders limited to adrenoleukodystophy (ALD) (including but not limited to AMN, CCALD,
and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to beta-thalassemia and sickle cell anemia), [***], the “Field” includes in vivo as well as ex vivo gene therapy.
Licensee and/or Affiliates shall have the right to request Institut Pasteur to expand the definition of “Field” to include additional clinical areas. [***] For clarity, the Field excludes any other fields and specifically prophylactic and
therapeutic human and veterinary vaccination against all kind of pathogens, and the field of services of production and commercialisation of Good Manufacturing Practice (GMP) batches of lentiviral vectors for clinical trials. For clarity, the Field
shall include production of GMP batches, by Licensee and its Affiliates [***]. For clarity, Institut Pasteur has already granted exclusive rights for services of production and commercialisation of Good Manufacturing Practice (GMP) batches of
lentiviral vectors for clinical trials. [***] 

  

	 	•	 	 “Improvement” shall mean any new invention, patentable or not, patented or not, of the Technology, which under applicable law, depends on, at
least, one claim of the Patents. For clarity, an Improvement does not include any Product. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

	 	•	 	 “Net Sales” shall mean the gross amount, excluded taxes, invoiced for sale of Products manufactured or sold in the Territory, in finish or
semi finish form by Licensee and/or Affiliates less the following items, consistent with U.S. GAAP: 

  

	 	a)	trade, quantity and cash discounts actually allowed; 

  

	 	b)	commissions, discounts, refunds, rebates, charge backs, retroactive price adjustments, and any other allowances paid to non-governmental Third Parties that effectively
reduce net selling price; 

  

	 	c)	credits, allowances and refunds for actual Product rejections, returns and allowances; 

 

	 	d)	taxes, duties and other governmental charges on the sale, shipment or transfer of the Product; and 

 

	 	e)	duly justified governmental discounts, refunds, rebates, charge backs, retroactive price adjustments and any other allowances that effectively reduce net selling price.

 It is understood that deductions set forth in a), b) and c) herein above shall not exceed [***] of gross
revenue, excluded taxes, invoiced for sale of Products in the Territory. 
  

	 	•	 	 “Patents” shall mean the patents and patents applications listed in Appendix 1, along with all other patent rights (including but not limited
to continuations, continuations-in-part (but only for those claims of such continuations-in-part that are fully supported by the patents and patent applications listed in Appendix 1 as of the Effective Date), divisionals, renewals, reissues,
re-examinations, patent term extensions) that claim priority in whole or in part to any such patents and patent applications. 

  

	 	•	 	 “Product” shall mean all composition or product for gene therapy or method in the Field that incorporate the Technology.

  

	 	•	 	 “Rare Diseases” shall include adrenoleukodystophy (ALD) (including but not limited to AMN, CCALD, and all other variants of this disease
caused by genetic mutations), beta hemoglobinopathies (including but not limited to beta-thalassemia and sickle cell anemia), [***]. Whether in the case of [***], such diseases shall be considered on a case-by-case basis and considered a Rare
Diseases if the incidence or prevalence is similar to those diseases listed as Rare Diseases above. In these situations, Licensee and/or Affiliates shall provide justification as to whether such disease is a Rare Disease, in writing, prior to
payment of the Milestone #4 or #5 as applicable. 

  

	 	•	 	 “Technology” shall mean lentivirus vector containing DNA flap sequence covered by whole or part of the claims of the Patents.

  

	 	•	 	 “Territory” shall mean [***]. 

  

	 	•	 	 “Third Party” shall mean any party which is not Institut Pasteur or Licensee or its Affiliates. 

Article 2. Scope 
 2.1. Under this
Agreement, Institut Pasteur grants to Licensee and its Affiliates, that Licensee and its Affiliates accepts at their own risks, a license under the Patents in the Field and in the Territory for research and development, and to manufacture, have
manufactured, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import or have imported the Products, to the exclusion of any other rights, which is: 

 

	 	•	 	 exclusive for Products containing human (HIV-1 and HIV-2) lentivirus vector, and ; 

 

	 	•	 	 non exclusive for Products containing non-human lentivirus vector. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 2.2. No right granted herein shall prevent Institut Pasteur or its licensees or research partners to
conduct research in the Field. 
 2.3. This Agreement includes the right for Licensee and/or Affiliates to grant sublicenses in the Field and
the Territory to and through multiple tier(s) of Third Party(ies). 
 Article 3. Licensee’s obligation 

3.1. Licensee shall make, or shall cause its Affiliates and sublicensee to make, all reasonable commercial efforts (by reference to a company of similar
size and scope to Licensee as of the Effective Date) to develop and commercialize one or more Products in the Field and to obtain any necessary governmental approvals in respect of, and market the Product(s) in the Field, if any. It is expressly
agreed that fulfillment of the above obligation is an absolute requirement for this Agreement to be maintained into force. 
 3.2. Licensee
shall provide annually, upon each anniversary date of the Effective Date, to Institut Pasteur an updated Development Plan, which will be Confidential Information of Licensee. [***] 
 3.3. Licensee is the sole responsible for securing the compliance of Products with applicable laws, rules and regulations, in particular, but without limitation, such as relating to ethics, the treatment
of animals, and genetically modified organisms, if any. 
 Article 4. Intellectual property 

4.1. The provisions of this Agreement shall not modify the ownership of the Technology and Patents. 

4.2. Any Improvement of the Technology made without Institut Pasteur by the Licensee shall belong to Licensee. 

4.3. Any Improvement of the Technology made with the help of Institut Pasteur will be co-owned by Institut Pasteur and Licensee. A specific agreement
shall be established between the co-owners within six (6) months following the identification of the joint Improvement. 
 4.4. Upon
request of Institut Pasteur, Institut Pasteur and Licensee agrees to meet in view to determine the conditions under which Licensee shall grant Institut Pasteur, a non exclusive, free license on the Improvement if possible and available mentioned in
articles 4.2 and 4.3 above, for internal research purpose. Licensee and/or Affiliates shall ask to Institut Pasteur to submit a supplementary protection certificate (SPC) for any Product. To this aim, Licensee shall provide Institut Pasteur all
necessary information. This SPC shall automatically be part of the Agreement. 
 4.5. From the Effective Date, Licensee shall pay to Institut
Pasteur [***] of future external expenses engaged by Institut Pasteur for securing issuance of, and maintaining Patents or extending the duration of the Patents. Institut Pasteur shall not abandon any Patent without the prior notice of Licensee.

 4.6. Upon written request, but at most once a year, Institut Pasteur shall keep Licensee informed of the status of issuance procedures of
Patents, and shall update Appendix 1 accordingly. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 4.7. Licensee acknowledges that Institut Pasteur has expended significant resources and efforts to
develop the Patents, and that the Patents represents highly valuable interests, [***]. 
 4.8. In the case a Patent is challenged (including but
not limited to a re-examination, opposition or interference proceeding, but not including when part of an infringement action described above), the Parties shall make available to the other all information they have, and shall meet to decide the
defense strategy. [***] 
 Article 5. Infringement 
 5.1. Institut Pasteur and Licensee shall as soon as they become aware thereof mutually advise each other of any infringement of Patents by a Third Party in the Field. Institut Pasteur and Licensee shall
make available to the other all information at their disposal on the basis of which nature and extend can be assessed. 
 5.2. [***] 

5.3. In the case Licensee is sued by a Third Party regarding Technology in a Product, the Parties shall make available to the other all information they
have, and shall meet to decide the defense strategy, if any, with respect to such Technology. 
 Article 6. Consideration 

6.1. Within thirty (30) days of the Effective Date, Licensee shall pay to Institut Pasteur a one-time, non-refundable license issuance fee [***]
exclusive of taxes. This amount cannot be set-off against future royalties. 
 6.2. For the development of each Product indication by
indication, except in the case mentioned below, Licensee and/or Affiliates shall pay to Institut Pasteur the following milestones: 
  

									
	 	  	[***]	  	[***]	  	[***]	  	[***]
	 Milestone 1: [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 Milestone 2: [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 Milestone 3: [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 Milestone 4: [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 Milestone 5: [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 Milestone 6: [***]
	  	[***]	  	[***]	  	[***]	  	[***]

 For the foregoing table: 
  

	 	•	 	 [***] 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

	 	•	 	 For each Product (including multiple indications for the same Product), only one column is applied and each milestone in such column is paid only once
at the first occurrence of such event 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

 For further
clarity, with respect to the second tabbed paragraph above, if the same Product is developed or approved for more than one indication, the specified milestones for a column shall be paid one time only at the first occurrence of such event. As a
specific example, [***]. 
 6.3. Until the expiration of the last Patent claiming a Product in the Territory, Licensee and/or Affiliates shall
pay to Institut Pasteur the following yearly royalty fees: 
  

	 	•	 	 [***] of Net Sales for a Product with an indication in a Rare Disease, without stacking clause, and 

 

	 	•	 	 [***] of Net Sales for a Product with an indication in a disease other than a Rare Disease, without stacking clause; 

[***]. 
 6.4. If the combined
royalties Licensee and/or Affiliates would be required to pay to Institut Pasteur and Third Parties, is higher than [***] for one Product, Licensee and/or Affiliates may ask Institut Pasteur to negotiate the royalty fees of the article 6.3.

 6.5. Licensee and/or Affiliates shall pay to Institut Pasteur a minimum annual fee [***] exclusive of taxes per twelve (12) month period
and due at the end of such period which shall start from the fifth anniversary of the Effective Date of this Agreement for all Products. For clarity, such payment shall be offset by the royalties payments made to Institut Pasteur during such 12
month period. If no Product is on the market after the fifth anniversary of the Effective Date, this minimum annual fee shall be reduced [***] exclusive of taxes until the first Product shall be on the market, date on which the minimum annual fee
shall be again [***] exclusive of taxes per twelve (12) month period. 
 6.6. Licensee and/or Affiliates shall pay to Institut Pasteur
[***] of all cash and cash-equivalent consideration, whatever its nature, and in particular without limitation, all sums, milestones, royalties, exchange value of any counterpart in kind or in industry (but not duly justified payments for research
and development) received by Licensee and/or Affiliates from its all sublicenses agreements granted by Licensee and/or Affiliates on the sole Technology. 
 6.7. On a indication-by-indication basis, in case of sublicenses relating to a Product, Licensee and/or Affiliates shall pay to Institut Pasteur on any and all cash and cash-equivalent consideration,
whatever its nature, and in particular without limitation, all sums, milestones, royalties, exchange value of any counterpart in kind or in industry (but not duly justified payments for research and development) received by Licensee and/or
Affiliates from a sublicensee: 
  

	 	•	 	 [***] if the sublicense is signed for Product(s) in a preclinical stage development, or, 

 

	 	•	 	 [***] if the sublicense is signed for Product(s) in a clinical stage of development. 

6.8. If the combined royalties Licensee and/or Affiliates would be required to pay to Institut Pasteur and Third Parties, is higher than [***] for one
Product, Licensee and/or Affiliates may ask Institut Pasteur to negotiate the royalty fees of the article 6.7. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 6.9. Notwithstanding the foregoing, in the case of a sublicense of the Technology for a Product for ALD
(including but not limited to AMN, CCALD, and all other variants of this disease caused by genetic mutations), beta-thalassemia and/or sickle cell anemia, Institut Pasteur shall receive the same Milestones and Royalties as if Licensee and/or
Affiliates itself were developing and commercializing such Product(s) (and thus no amounts shall be payable to Institut Pasteur under Article 6.7). Licensee and/or Affiliates shall be liable for ensuring such payment in accordance with the terms of
this Agreement. 
 Article 7. Payment 
 7.1. Payment of royalties due under this Agreement shall be made within forty-five (45) days from the invoice date, after the end of each six-month period’s Net Sales (ending 30 June and 31
December) for the sum corresponding to that period. 
 7.2. Any payment due by Licensee, pursuant to this Agreement, shall be made in euros by
check or by wire transfer to a bank account as designated by Institut Pasteur from time to time. 
 7.3. Royalties arising out of Net Sales
achieved in currencies other than the Euro shall be converted at the current average exchange rate one month prior to the date upon which the royalties report is due, and shall be borne by Licensee. 

7.4. Notwithstanding the provisions of this Agreement, sums paid to Institut Pasteur shall in any event be retained by Institut Pasteur. Any VAT (Value
Added Tax) due, if any, shall be added to the invoiced amount at the then current rate, and shall be borne by Licensee. 
 7.5. Any withholding
tax payable by Licensee on royalties due hereunder shall be deducted from royalties due for the relevant country. Licensee shall be responsible for obtaining and providing to Institut Pasteur evidence of the payment of such withholding taxes.
Licensee shall assist Institut Pasteur to prevent any double taxation and shall provide Institut Pasteur on request with any document necessary to that end. 
 7.6. The royalties and other payments set forth in this Agreement shall, if overdue, bear interest until paid at a per annum rate of [***]. The payment of such interest shall not foreclose Institut
Pasteur from exercising any other rights or actions it may have as a consequence of the lateness of any payment. 
 Article 8. Accounts

 8.1. Licensee shall simultaneously with payments of royalties deliver to Institut Pasteur a report reflecting its accounts and
sub-licenses accounts, pertaining to royalties calculated, on Net Sales, including: 
  

	 	•	 	 [***]; 

  

	 	•	 	 [***]; and 

  

	 	•	 	 [***]. 

 Such report maybe
delivered by email to the following email address (which address may be updated by written notice from Institut Pasteur to Licensee): Service de Transfert de Technologie, [***]. 
 8.2. When no royalty is payable, a report so attesting shall be submitted to Institut Pasteur. The aforesaid reports shall be treated as Confidential Information of Licensee. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 Such report maybe delivered by email to the following email address (which address may be updated by
written notice from Institut Pasteur to Licensee): Service de Transfert de Technologie, [***]. 
 8.3. Licensee shall keep complete and accurate
records of all Net Sales, allowing a computation and checking of the royalty amount due to Institut Pasteur hereunder. Once a year and upon prior notice to Licensee and/or Affiliates, Institut Pasteur shall, throughout the term of this Agreement,
and for a period of three (3) years following the end of this Agreement, be entitled to have at its own expense and during regular business hours Licensee’s records pertaining to this Agreement checked by an independent certified public
accountant chosen by Institut Pasteur and reasonably acceptable to Licensee, which accountant shall enter into a confidentiality agreement with Licensee. Such accountant shall be appointed for the sole purpose of determining the amount of royalties
due to Institut Pasteur hereunder, covering a period not to exceed the past three (3) years, provided that [***] such accountant shall report to Institut Pasteur only as to the accuracy of royalty statements and payments and that such reported
information shall be considered to be Confidential Information of Licensee. 
 8.4. If, as a result of such audit, an adjustment is determined
to be made in favor of Institut Pasteur, the accountant’s fees and expenses shall be borne by Licensee, if the sums underpaid by Licensee exceed [***] of what was actually paid by Licensee to Institut Pasteur; otherwise such fees and expenses
shall be paid by Institut Pasteur. Licensee shall pay any underpaid royalties to Institut Pasteur. 
 Article 9. Confidentiality

 9.1. Confidential Information does not include information for which it is evidenced that: 

 

	 	•	 	 is publicly known and made generally available in the public domain prior to the time of disclosure by the providing Party,

  

	 	•	 	 becomes publicly known and made generally available after disclosure by the providing Party to the receiving Party through no action or inaction of the
receiving Party, 

  

	 	•	 	 is already in the possession of the receiving Party at the time of disclosure by the providing Party as shown by the receiving Party’s documentary
evidence, 

  

	 	•	 	 is obtained by the receiving Party from a Third Party without breach of such Third Party’s obligations of confidentiality, as shown by the
receiving Party’s documentary evidence, 

  

	 	•	 	 is required by law to be disclosed by the receiving Party. 

 9.2. In the event that the receiving Party is notified of a requirement to disclose the providing Party’s Confidential Information, the receiving Party shall notify the providing Party immediately
upon receipt of such notice and not release the Confidential Information until such time as the providing Party has taken reasonable steps to seek an order of a court of competent jurisdiction to prevent the disclosure, or limit the extent of
disclosure, of the providing Party’s Confidential Information. 
 9.3. During the term of this Agreement and five (5) years
thereafter, the receiving Party agrees to keep confidential and cause its employees, consultants or students to keep confidential, all Confidential Information of the providing Party that is disclosed to it, or to any of its employees, consultants
or students under or in connection with this Agreement. 
 9.4. Neither the receiving Party nor any of its respective employees, consultants or
students, shall use Confidential Information for any other purpose whatsoever except as expressly permitted by this Agreement. 
 9.5. The
receiving Party may not disclose providing Party’s Confidential Information to a Third Party without the prior written consent of the providing Party, other than for Licensee and/or Affiliates in connection with a proposed or actual sublicense
or transaction permitted by Article 13.7 or for other reasonable business purposes, subject to the confidentiality protections stated above, for the purpose of this Agreement. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 9.6. Following expiration or termination of this Agreement, the receiving Party shall return all the
Confidential Information to the providing Party, or destroy such Confidential Information at the providing Party request, with the exception that (1) one copy of the Confidential Information that may be retained by the receiving Party’s
legal counsel for the purpose of verifying its obligations under this Agreement. 
 Article 10. Representations and Warranties

 10.1. At the Effective Date, each Party represents and warrants to the other Party that it has the right to enter into this Agreement.

 10.2. Licensee agrees that all Confidential Information or any other information or data communicated or provided by Institut Pasteur under
this Agreement are communicated “as is”, without any warranty, expressed or implied, regarding accuracy, completeness, merchantability, fitness, patentability and/or performance. Any hazards, costs and risks that may be incurred by
Licensee in connection with the use of all or part of the Products, resulting, in particular, from possible defects or from the eviction risk, are the sole responsibility of Licensee. Institut Pasteur shall not be liable for any consequential,
indirect or punitive damages or lost profits of Licensee. 
 10.3. Institut Pasteur gives no warranty whatsoever express or implied, in respect
of the Patents, in particular as regards of its usefulness, safety or fitness for a particular purpose. Institut Pasteur does not, either expressly or tacitly warrant that the use of the Patents granted under this Agreement shall allow the
production of Product, as well as the manufacture, sale, use, importation, exportation and holding of Products shall not infringe a Third Party’s intellectual proprietary rights or violate any rights in particular license rights, already
granted to a Third Party. Licensee undertakes not to enforce any remedy, including a claim under any guarantee against Institut Pasteur, for compensation of whatever damage which might arise out of or in connection with the use or non use of the
Patents. 
 10.4. Nothing in the Agreement shall be construed as: (a) a warranty or representation by Institut Pasteur as to the validity
or scope of any Patents; (b) a warranty or representation by Institut Pasteur that the practice under the Patents is or will be free from infringement of patents of any Third Party or rights granted to Third Party; (c) except as expressly
set forth herein, an obligation to Institut Pasteur to sue Third Party for infringement; or (d) conferring by implication, estoppels or otherwise any license, immunity or right under any patent owned by or licensed to Institut Pasteur other
than the Patents. 
 10.5. Institut Pasteur shall under no circumstances be held liable to Licensee, whether expressly or impliedly, for any
direct, indirect, consequential or special damages in relation to the use or sale of Patents and/or Products by Licensee. Licensee shall indemnify and hold Institut Pasteur harmless from all costs and expenses of any kind, arising from or resulting
of any Third Party claim against Institut Pasteur relating to the use, handling or storage by Licensee of the Patents or Confidential Information, as well as the manufacture, sale, use, importation, exportation and holding of Product, except where
such claims arise from a finding of gross negligence or willful misconduct by Institut Pasteur only with respect to the Patents or Confidential Information, to the exclusion of Products. [***] 

10.6. Institut Pasteur may terminate this Agreement with immediate effect in the event that Licensee, either directly or indirectly, or its Affiliates
challenges the validity of any of the Patents. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 Article 11. Term and Termination 
 11.1. This Agreement shall be effective from the Effective Date. 
 11.2. Unless sooner terminated
under the articles below, this Agreement shall be effective until the last Patents to expire in the Territory. 
 11.3. This Agreement may be
terminated without any indemnification, by either Party at any time during this Agreement if the other Party is in substantial breach of its obligations hereunder and has not cured such breach within sixty (60) days after a registered letter
notifying such substantial breach, without prejudice of any right to pursue an action for damages as a result of such breach. 
 11.4. Institut
Pasteur may also terminate this Agreement without fault where collective proceedings – bankruptcy, suspension of proceedings – are opened against Licensee and not dismissed within sixty (60) days thereafter. 

11.5. Licensee may terminate this Agreement by a written notice sent ninety (90) days in advance. 

11.6. Termination of this Agreement for any reason shall not affect each Party’s continuing obligations to the other Party under this Agreement or
pursuing provisions. Upon termination of this Agreement, as long as there are always unexpired Patents under the Territory, this license shall automatically terminate and Licensee shall promptly cease any use of the Patents and shall cease
manufacturing, importing, using and selling Products within [***] form the effective date of the termination. 
 11.7. Upon termination of this
Agreement, Institut Pasteur shall have the right to retain any sums already paid by Licensee hereunder, and Licensee shall pay all sums accrued hereunder which are then due, including all sums generated during the three month period mentioned in
Article 11.6 of this Agreement. 
 11.8. Articles 1, 3.3, 4.1 to 4.3, 7 to 10, 11.6, 11.7, 11.8 and 12 shall survive any termination or
expiration of this Agreement. 
 Article 12. Litigation and governing law 
 12.1. This Agreement shall be construed and governed by the Laws of France. The language of this Agreement shall be English. 
 12.2. The Parties shall attempt to settle any dispute relating to this Agreement, its validity and/or its interpretation and/or its enforceability and/or its termination, in an amicable way. Should such
attempts fails, the litigation will be held in the court of the competent jurisdiction in France. 
 Article 13. Miscellaneous

 13.1. This Agreement contains the entire understanding and agreement between the Parties hereto with respect to its subject matter, and
except where otherwise provided herein, supersedes any prior or contemporaneous written or oral agreement between them relating to the subject matter hereof. 
 13.2. The Parties agree to keep the existence and the terms and conditions of this Agreement strictly confidential, and shall not disclose the existence and the terms and conditions of this Agreement to
any Third 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
Party, except as required by law (including but not limited to in connection with a public securities offering) or by Licensee in connection with a proposed or actual sublicense or transaction
permitted by Article 13.7 or for other reasonable business purposes. Moreover, nothing contained in this Agreement shall grant to Licensee a right to use for advertising, publicity or any promotional activity whatsoever Institut Pasteur’s
names, trademarks, logo or any other designations, including in contracted or abbreviated form or by imitation, subject to a prior express written consent of Institut Pasteur. Notwithstanding the foregoing, Licensee may disclose the existence of
this Agreement and the fact that Institut Pasteur has granted an exclusive license under the Patents to Licensee. 
 13.3. This Agreement may be
amended only by a written amendment signed by the Parties. 
 13.4. If any term, provision or condition of this Agreement shall be held by a
court of competent jurisdiction to be invalid, unenforceable or void, the remainder of this Agreement shall remain in full force and effect. 

13.5. Any notice required or permitted to be given under this Agreement shall be sufficient if sent by commercial courier or certified mail (return
receipt requested), facsimile, or postage prepaid, addressed to the address mentioned in first page of this Agreement. 
 13.6. Neither Party
shall be liable to the other for any default under this Agreement caused by war, riot, fire, flood, drought, act of God or any other cause which is beyond the reasonable control of the defaulting Party, as acknowledged by the court of competent
jurisdiction. 
 13.7. This Agreement being entered into for the benefit of consideration of the Parties, shall not be assigned or transferred,
whether in whole or in part, without the other Party’s prior written consent; provided that Licensee may assign this Agreement to an Affiliate or in connection with the merger, consolidation, or sale of all or substantially all of its assets or
that portion of its business pertaining to the subject matter of this Agreement, and the assignee shall notify Institut Pasteur of such assignment and shall agree in writing to be bound to the terms of this Agreement as “Licensee”
hereunder. 
 13.8. The relationship created by this Agreement shall be that of independent contractors. 

13.9. The failure or neglect of a Party at any time, to require performance of the other Party of any provision hereof, shall not in any way affect the
right to require such performance at any time thereafter. The waiver by a Party of any breach of any provision hereof shall not be held to be a waiver of any subsequent breach of the same provision or of any other provisions hereof. 

[remainder of this page intentionally left blank] 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their authorized respective
representative. 
 Made in Paris, 
 In
duplicate. 
  

					
	 Date: 08 SEP. 2011
  

/s/ Christophe Mauriet
	 		 	 Date: 13-Sept 2011
  

/s/ Nick Leschly

	 INSTITUT PASTEUR
 Christophe
Mauriet
 Senior Executive Vice-President
	 		 	 BLUEBIRDBIO INC.
 Nick
Leschly
 Chief Executive Officer

			
	 Date: 26/8/11
  

/s/ Jean Derégnaucourt
 INSTITUT PASTEUR
 Jean Derégnaucourt
 Executive Vice-President Business Development
	 		 	

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 Appendix 1 
 Patents 
  

					
	 Invention
	  	Priority/Filing
date
Extension/Filing date	  	Territories / Filing date
Legal 
Status
	 [***]
	  		  	

 Institut Pasteur hereby confirms that the foregoing is a complete and accurate list of all the Patents as the Date of
August 11,2011. 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 AMENDMENT N°1 TO THE LICENSE AGREEMENT 

Between 
 INSTITUT PASTEUR, a non profit
private foundation organized under the laws of France with offices at 25-28 rue du Docteur Roux, 75 724 Paris Cedex 15, France, VAT FR 65 775 684 897, represented by M. Christophe Mauriet, Senior Executive Vice-President for Administration

 Hereinafter referred to as “Institut Pasteur” 
 On one hand, 
 And 
 BLUEBIRDBIO INC., a company incorporated under the laws of Massachusetts, with offices at 840 Memorial Drive, Cambridge, MA 02139, United States, represented by Nick Leschly, Chief Executive
Officer 
 Hereinafter referred to as “Licensee”, 
 On the other hand, 
 Hereinafter mentioned as a Party or the Parties. 

Recitals 
 1. The Parties have signed a
license agreement on September 13, 2011 on a patented specific nucleotide sequence having a triplex structure, referred to as “DNA flap”. 
 2. Institut Pasteur has granted several exclusive or non exclusive licenses on the DNA flap under several fields to companies, [***]. 
 3. Institut Pasteur has negotiated with a licensee to obtain rights for the Licensee in this field of services of production and commercialization of Good Manufacturing Practice (GMP) batches of
lentiviral vectors for clinical trials, according to the terms and conditions of this Amendment n°1. 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 Now, therefore, the Parties hereby agree as follow: 

Article 1. Scope 
 The scope of this
Amendment n°1 is to extend the Field of the Agreement and the license grants by Institut Pasteur. 
 Article 2. Modifications

 2.1. The definition of the Field in the article 1 of the Agreement is replaced by the following definition as from the effective date of
this Amendment n°1: 
  

	 	•	 	 “Field” shall mean ex vivo gene therapy for human disorders limited to adrenoleukodystophy (ALD) (including but not limited to AMN, CCALD,
and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to beta-thalassemia and sickle cell anemia), [***] for [***] the “Field” includes in vivo as well as ex vivo gene
therapy. [***] 

 2.2. The article 2.1 of the Agreement is modified as follow, as from the effective date of this Amendment
n°1: 
 “2.1. Institut Pasteur hereby grants to Licensee, its Affiliates, that Licensee, its Affiliates accept at their own risk, a
license under the Patents in the Field and in the Territory for research and development, and to manufacture, have manufactured, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import or have imported the
Products, to the exclusion of any other rights, the said license being: 
  

	 	•	 	 exclusive for Products containing human (HIV-1 and HIV-2) lentivirus vector; 

 

	 	•	 	 nonexclusive for Products containing non-human lentivirus vector. 

 In addition, Institut Pasteur hereby grants to Licensee, its Affiliates and sublicensees, that Licensee, its Affiliates and sublicensees accept at their own risk, a nonexclusive license under the Patents
in the Field and in the Territory to make or to have made by a Thirty Party Good Manufacturing Practice (GMP) batches of lentiviral vectors for its/their own clinical trials on Products, provided that such Third Party makes Good Manufacturing
Practice (GMP) batches of lentiviral vectors solely for the Licensee, its Affiliates and sublicensees clinical trials of Products above mentioned. 
 2.3. The article 10.5 of the Agreement is modified as follow, as from the effective date of this Amendment n° l: the last sentence of such article 10.5 is modified as follow: [***] 

Article 3. Miscellaneous 
 3.1. All the
other provisions of the Agreement remain unchanged and fully applicable between the Parties. 
 3.2. This Amendment n°1 is effective from
the date of signature by the Parties. 
 3.3. This Amendment n°1 makes integral part of the Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their authorized respective
representative. 
 Made in Paris, 
 In
duplicate. 
  

					
	 Date: 27 AVR. 2012
  

/s/ Christophe Mauriet
	 		 	 Date:
  

/s/ Nick Leschly

	 INSTITUT PASTEUR
 Christophe
Mauriet
 Senior Executive Vice-President
	 		 	 BLUEBIRDBIO INC.
 Nick
Leschly
 Chief Executive Officer

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 AMENDMENT N°2 TO THE LICENSE AGREEMENT 

Between 
 INSTITUT PASTEUR, a non profit
private foundation organized under the laws of France with offices at 25-28 rue du Docteur Roux, 75 724 Paris Cedex 15, France, VAT FR 65 775 684 897, represented by M. Christophe Mauriet, Senior Executive Vice-President for Administration

 Hereinafter referred to as “Institut Pasteur” 
 On one hand, 
 And 
 BLUEBIRDBIO INC., a company incorporated under the laws of Delaware, with offices at 840 Memorial Drive, Cambridge, MA 02139, United States, represented by Nick Leschly, Chief Executive Officer

 Hereinafter referred to as “Licensee”, 
 On the other hand, 
 Hereinafter mentioned as a Party or the Parties. 

Recitals 
 1. The Parties have signed a
license agreement on September 13, 2011 on a patented specific nucleotide sequence having a triplex structure, referred to as “DNA flap”, modified by an amendment n°1 dated April 27, 2012 (the “Agreement”).

 2. The Licensee has initiated a program to treat cancerous and/or pre-cancerous conditions by genetically modifying T cells to express
antigen binding domain(s) on their surface that target tumor associated antigen(s). 
 3. Institut Pasteur agrees to extend the Field as
follows, and the Parties agree to modify some definitions, according to the terms and conditions of this Amendment n°2. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 Now, therefore, the Parties hereby agree as follow: 

Article 1. Scope 
 The scope of this
Amendment n°2 is to extend the Field of the Agreement and the license granted by Institut Pasteur, and to make some modifications. 

Article 2. Modifications 
 2.1. The
following definitions shall replace the definitions of the Agreement: 
  

	 	•	 	 “Gene therapy” shall mean the use of a vector containing at least one DNA sequence that encodes at least one protein, in order to restore the
functional activity of one or more resident non-functional gene copies, or provide for the introduction and expression of novel protein(s) not normally expressed in the cell type or expression of protein(s) that do not exist normally in nature. The
introduced protein(s) are not intended to generate a prophylactic and/or therapeutic immune response against the protein encoded by the introduced DNA sequence of interest for use in Vaccination. 

 

	 	•	 	 “Ex vivo” shall mean that cells are extracted from a patient, corrected or otherwise modified by Gene Therapy, and transplanted or dosed back
into patient. 

  

	 	•	 	 “Vaccination” shall mean the use of a vector containing at least one DNA sequence that encodes at least one protein with the intent to
generate an immune response against the protein encoded by the DNA sequence of interest to cause a prophylactic or therapeutic effect in humans and other animals. The protein encoded by the DNA sequence of interest shall not restore an altered or
non existing protein function or, modify existing protein function. 

  

	 	•	 	 “Field” shall mean ex vivo Gene therapy for human disorders limited to adrenoleukodystophy (ALD) (including but not limited to AMN, CCALD,
and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to beta-thalassemia and sickle cell anemia), [***] leukemias, lymphomas, B-cell malignancies and solid tumors by producing
chimeric antigen receptor T-cells [***] for [***] and [***] the “Field” includes in vivo as well as ex vivo Gene therapy. [***] 

 2.2. The following sentence is hereby added to the end of Article 2.1 of the Agreement: “At Licensee’s request, the Parties agree to discuss in good faith about the [***].” 

2.3. The following sentence is hereby added to the end of Article 4.4 of the Agreement: “Further, Licensee shall have the right to seek patent term
extension according to the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman) for any Patent based on Product(s) (in addition to an SPC(s) as provided in Article 4.4). Institut Pasteur will reasonably assist Licensee if
Licensee elects to initiate to obtain any such patent term extension”. 
 Article 3. Other Terms 

3.1. Upon signature of this Amendment 2 by the Parties, Licensee shall pay Institut Pasteur [***] exclusive of taxes. This amount cannot be set-off
against future royalties. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 Article 4. Miscellaneous 
 4.1. All the other provisions of the Agreement remain unchanged and fully applicable between the Parties. 
 4.2. This Amendment n°2 is effective from the date of signature by the Parties. 
 4.3. This
Amendment n°2 makes integral part of the Agreement. 
 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
authorized respective representative. 
 Made in Paris, 
 In duplicate. 
  

					
	 Date: 16 OCT. 2012
  

/s/ Christophe Mauriet
	 		 	 Date: 16 OCT. 2012
  

/s/ Nick Leschly

	 INSTITUT PASTEUR
 Christophe
Mauriet
 Senior Executive Vice-President
	 		 	 BLUEBIRDBIO INC.
 Nick
Leschly
 Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]